We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 28, 2016

Paclitaxel Plus Bevacizumab vs Paclitaxel as First-Line Treatment for HER2-Negative Metastatic Breast Cancer

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Paclitaxel Plus Bevacizumab or Paclitaxel as First-Line Treatment for HER2-Negative Metastatic Breast Cancer in a Multicenter National Observational Study
Ann. Oncol 2016 Jul 19;[EPub Ahead of Print], S Delaloge, D Pérol, C Courtinard, E Brain, B Asselain, T Bachelot, M Debled, V Dieras, M Campone, C Levy, W Jacot, V Lorgis, C Veyret, F Dalenc, JM Ferrero, L Uwer, P Kerbrat, A Goncalves, MA Mouret-Reynier, T Petit, C Jouannaud, L Van Lemmens, G Chenuc, T Guesmia, M Robain, C Cailliot

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading